Form 4 for BSX Boston Scientific
Accepted 2026-02-18 00:00:00 ET · period of report 2026-02-13 · accession 0001225208-26-002134 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-18 | 2026-02-13+ | BSX | Fitzgerald Joseph Michael | EVP, Group Pres, Cardiology | F - Tax | $74.73 | -36.9K | 211.8K | -15% | -$2.76M |
| DM | 2026-02-18 | 2026-02-13+ | BSX | Fitzgerald Joseph Michael | EVP, Group Pres, Cardiology | M - OptEx | $0.00 | +11.1K | 242.5K | +5% | $0 |
| DM | 2026-02-18 | 2026-02-13 | BSX | Fitzgerald Joseph Michael | EVP, Group Pres, Cardiology | A - Grant | $0.00 | +69.8K | 204.8K | +52% | $0 |
| DM | 2026-02-18 | 2026-02-13+ | BSX | Fitzgerald Joseph Michael | EVP, Group Pres, Cardiology | M - OptEx | $0.00 | -11.1K | 8,391 | -57% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-16 | F | D | 1,806 | $74.73 | 213,907 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-16 | M | A | 3,960 | $0.00 | 215,713 | D | — | — | (F3) Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. |
| 3 | Common | Common Stock | 2026-02-14 | M | A | 4,362 | $0.00 | 213,743 | D | — | — | (F3) Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. |
| 4 | Common | Common Stock | 2026-02-13 | F | D | 33,104 | $74.73 | 209,381 | D | — | — | |
| 5 | Common | Common Stock | 2026-02-14 | F | D | 1,990 | $74.73 | 211,753 | D | — | — | |
| 6 | Common | Common Stock | 2026-02-13 | M | A | 2,797 | $0.00 | 242,485 | D | — | — | (F3) Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. |
| 7 | Common | Common Stock | 2026-02-13 | A | A | 34,898 | $0.00 | 239,688 | D | — | — | |
| 8 | Common | Common Stock | 2026-02-13 | A | A | 34,898 | $0.00 | 204,790 | D | — | — | |
| 9 | Derivative | Restricted Stock Units | 2026-02-16 | M | D | 3,960 | $0.00 | 0 | D | — · — to 2026-02-16 | 3,960 Common Stock | (F3) Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. (F7) Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. |
| 10 | Derivative | Restricted Stock Units | 2026-02-14 | M | D | 4,362 | $0.00 | 4,363 | D | — · — to 2027-02-14 | 4,362 Common Stock | (F3) Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. (F6) Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. |
| 11 | Derivative | Restricted Stock Units | 2026-02-13 | M | D | 2,797 | $0.00 | 8,391 | D | — · — to 2029-02-13 | 2,797 Common Stock | (F3) Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. (F5) Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. |